| Name | Title | Contact Details |
|---|
Serving markets in the US and Canada, Vision Group Holdings oversees and manages the leading LASIK and laser eye surgery providers in North America.
Kalispell Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Kalispell Regional Medical Center is based in Kalispell, MT. You can find more information on Kalispell Regional Medical Center at www.krmc.org
Great Plains Orthotics and Prosthetics is a Ames, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Proudly serving the community since 1952, Tahoe Forest Hospital is a not for profit rural health care facility and designated Critical Access Hospital. It is fully accredited by the Healthcare Facilities Accreditation Program and licensed by the State of California Department of Health Services. Tahoe Forest Hospital has 25 acute care beds and 36 long-term care beds. Our geographic area covers six rural counties, two states and approximately 3,500 square miles with primary services reaching the communities of Truckee, North Lake Tahoe, Donner Summit and the Sierra Valley in California and Incline Village in Nevada. Tahoe Forest Hospital serves a full-time population of approximately 40,000 residents with influxes of up to an additional 30,000 tourists during peak periods.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.